% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{AfsharOromieh:126018,
      author       = {A. Afshar-Oromieh$^*$ and H. Hetzheim$^*$ and C.
                      Kratochwil$^*$ and M. Benesova$^*$ and M. Eder$^*$ and O.
                      Neels$^*$ and M. Eisenhut$^*$ and W. Kübler$^*$ and T.
                      Holland-Letz$^*$ and F. Giesel$^*$ and W. Mier$^*$ and K.
                      Kopka$^*$ and U. Haberkorn$^*$},
      title        = {{T}he {T}heranostic {PSMA} {L}igand {PSMA}-617 in the
                      {D}iagnosis of {P}rostate {C}ancer by {PET}/{CT}:
                      {B}iodistribution in {H}umans, {R}adiation {D}osimetry, and
                      {F}irst {E}valuation of {T}umor {L}esions.},
      journal      = {Journal of nuclear medicine},
      volume       = {56},
      number       = {11},
      issn         = {0161-5505},
      address      = {Reston, Va.},
      publisher    = {SNM58412},
      reportid     = {DKFZ-2017-02133},
      pages        = {1697-1705},
      year         = {2015},
      abstract     = {PET imaging with the prostate-specific membrane antigen
                      (PSMA)-targeted radioligand (68)Ga-PSMA-11 is regarded as a
                      significant step forward in the diagnosis of prostate cancer
                      (PCa). More recently, a PSMA ligand was developed that can
                      be labeled with (68)Ga, (111)In, (177)Lu, and (90)Y. This
                      ligand, named PSMA-617, therefore enables both diagnosis and
                      therapy of PCa. The aims of this evaluation were to
                      clinically investigate the distribution of (68)Ga-PSMA-617
                      in normal tissues and in PCa lesions as well as to evaluate
                      the radiation exposure by the radioligand in PET
                      imaging.Nineteen patients, most of them with recurrent PCa,
                      were referred for (68)Ga-PSMA-617 PET/CT. The quantitative
                      assessment of tracer uptake of several organs and of 53
                      representative tumor lesions was performed in 15 patients at
                      1 and 3 h after injection. In 4 additional patients, the
                      same procedure was conducted at 5 min, 1 h, 2 h, 3 h, 4 h,
                      and 5 h after injection. On the basis of the data for these
                      4 patients (mean injected dose, 231 MBq), the radiation
                      exposure of a (68)Ga-PSMA-617 PET/CT was identified.Intense
                      tracer uptake was observed in the kidneys and salivary
                      glands. In 14 of 19 patients $(73.7\%),$ at least 1 lesion
                      suspected of being a tumor was detected at 3 h after
                      injection. Of 53 representative tumor lesions selected at 3
                      h after injection, 47 lesions were visible at 1 h after
                      injection. The mean tumor-to-background ratio for maximum
                      standardized uptake value was 20.4 ± 17.3 (range, 2.3-84.0)
                      at 1 h after injection and 38.2 ± 38.6 (range, 3.6-154.3)
                      at 3 h after injection. The average radiation exposure
                      (effective dose) was approximately 0.021 mSv/MBq.Within
                      healthy organs, the kidneys and salivary glands showed the
                      highest (68)Ga-PSMA-617 uptake. The radiation exposure was
                      relatively low. (68)Ga-PSMA-617 shows PCa lesions with high
                      contrast. Images obtained between 2 and 3 h after injection
                      seem to be the best option with regard to radiotracer uptake
                      and tumor contrast. Later images can help to clarify unclear
                      lesions.},
      keywords     = {(68Ga)Glu-urea-Lys(Ahx)-HBED-CC (NLM Chemicals) /
                      Dipeptides (NLM Chemicals) / Gallium Radioisotopes (NLM
                      Chemicals) / Heterocyclic Compounds, 1-Ring (NLM Chemicals)
                      / Organometallic Compounds (NLM Chemicals) / PSMA-617 (NLM
                      Chemicals) / Radiopharmaceuticals (NLM Chemicals) /
                      Prostate-Specific Antigen (NLM Chemicals)},
      cin          = {E060 / E020 / E030 / W060 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)E020-20160331 /
                      I:(DE-He78)E030-20160331 / I:(DE-He78)W060-20160331 /
                      I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:26294298},
      doi          = {10.2967/jnumed.115.161299},
      url          = {https://inrepo02.dkfz.de/record/126018},
}